Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea.
The present report is based on an analysis of the evolution of 720 cases of Polycythaemia vera treated with pipobroman and 624 cases treated with hydroxyurea. General modes of treatment are identical for the two drugs, consisting of initial therapy at relatively high dose aimed at obtaining complete remission and maintenance therapy essential to conserve the improved clinical status. Both types of treatment must be adapted to suit the patient. Complete remission is achieved in 95 to 100% of cases with pipobroman and in 80 to 90% of cases with hydroxyurea. Incidents which may occur during initial therapy include cytopenia, more frequent and severe under treatment with hydroxyurea, rare transitory digestive troubles and cutaneous and mucous eruptions. Subject to control of the blood cell count every three to four months, maintenance therapy may be continued for many years and while the time lapse is as yet insufficient for hydroxyurea, resistance to pipobroman does not appear to develop even after more than 20 years of treatment. Although neither of these two drugs entirely avoids the occurrence of acute leukaemia which appears in 5 to 8% of subjects irrespective of the duration of therapy, on the contrary to observations in patients treated by bleeding alone, myeloid splenomegaly with myelofibrosis is rare and develops in no more than 2% of cases. The frequency of visceral cancers is not increased by either drug. Provided Polycythaemia vera is maintained in complete remission, thrombotic accidents occur no more often than in a normal population of the same age bracket.(ABSTRACT TRUNCATED AT 250 WORDS)
Boivin
P
P
Service d'Hématologie Clinique, Hôpital Beaujon, Clichy, France.
D000208:Acute Disease; D001815:Bloodletting; D003131:Combined Modality Therapy; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use*; D007938:Leukemia / Q000209:etiology; D010761:Phosphorus Radioisotopes / Q000009:adverse effects; D010885:Pipobroman / Q000009:adverse effects / Q000627:therapeutic use*; D011087:Polycythemia Vera / Q000150:complications / Q000188:drug therapy* / Q000628:therapy*; D013163:Splenomegaly / Q000209:etiology; D014652:Vascular Diseases / Q000209:etiology
D010761:Phosphorus Radioisotopes; D010885:Pipobroman; D006918:Hydroxyurea